These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10860003)

  • 1. Basic safety pharmacology: the cardiovascular system.
    Lacroix P; Provost D
    Therapie; 2000; 55(1):63-9. PubMed ID: 10860003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The respiratory system and safety pharmacology].
    Touvay C; Le Mosquet B
    Therapie; 2000; 55(1):71-83. PubMed ID: 10860004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Place and role of safety pharmacology in drug development].
    Guillon JM
    Ann Pharm Fr; 2010 Sep; 68(5):291-300. PubMed ID: 20850000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety pharmacology: central nervous system].
    Rambert FA
    Therapie; 2000; 55(1):55-61. PubMed ID: 10860002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety and the role of clinical pharmacology in the safe use of therapeutics.
    Honig PK
    Clin Pharmacol Ther; 2009 Mar; 85(3):225-8. PubMed ID: 19223873
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacodynamic effects in the cardiovascular system: the modeller's view.
    Fink M; Noble D
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):243-9. PubMed ID: 20470255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL
    Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology.
    Chain AS; Sturkenboom MC; Danhof M; Della Pasqua OE
    Drug Discov Today Technol; 2013 Sep; 10(3):e373-83. PubMed ID: 24050134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of some pharmacological methods used in safety pharmacology studies.
    Pugsley MK
    Proc West Pharmacol Soc; 2004; 47():18-22. PubMed ID: 15633602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal safety pharmacology: value of sensitized experimental models.
    Idée JM
    Therapie; 2000; 55(1):91-6. PubMed ID: 10860006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular pharmacology. An example of the need of clinically relevant pharmacological research].
    Raberger G; Krumpl G; Fischer G; Grohs JG; Todt H; Krejcy K; Huber S; Brugger G; Karel A; Krivanek P
    Wien Klin Wochenschr; 1990 Oct; 102(20):593-601. PubMed ID: 2256341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1.
    Harada N; Hoshiai K; Takahashi Y; Sakaguchi Y; Kuno T; Hishida T; Shiku H
    Kobe J Med Sci; 2008 May; 54(1):E23-34. PubMed ID: 18772606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we tolerate tolerability as an objective in early drug development?
    Cohen A
    Br J Clin Pharmacol; 2007 Sep; 64(3):249-52. PubMed ID: 17716332
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.